Factors such as growing focus on developing alternatives for animal testing models, technological advancements, and the development of new 3D in vitro models are expected to drive market growth.
Browse 42 market data Tables and 0 Figures spread through 100 Pages and in-depth TOC on "In Vitro Lung Model Market"
Early buyers will receive 10% customization on reports.
2D models are expected to account for the largest share of the lung in vitro models market in 2018
Based on type, the market is segmented into 2D cell models and 3D cell models. The 2D models segment is expected to account for the largest share of the market owing to its use historically. Additionally 2D models/cell lines are used in the research and development of 3D models. However, the 3D cell models segment is projected to grow at the fastest rate during the forecast period owing to the rising need for efficient lung in vitro models that mimic in vivo physiology.
The drug discovery and toxicology applications of 3D models are expected to grow at the highest CAGR during the forecast period
Based on application, the market is segmented applications of 2D models and 3D models. Applications of 3D models include drug discovery and toxicology, physiological research, and stem cell research & regenerative medicine. The drug discovery and toxicology segment is also expected grow at the highest CAGR during the forecast period owing to increasing adoption of 3D models in this area.
North America to command the largest share of the lung in vitro models market in 2018
North America held the largest share of the lung in vitro models market in 2017. Flourishing research environment and abundant funding programs from organizations such as the National Institutes of Health (NIH) and increased R&D activities by biotechnology and pharmaceutical companies are driving the growth of the lung in vitro models market in North America.
The major players in the Lung in vitro models market include Epithelix (Switzerland), MatTek Corporation (US), Lonza (Switzerland), ATCC (US), InSphero (Switzerland), Emulate (US), AlveoliX (Switzerland), Oncotheis (Switzerland), Insphero (Switzerland), TissUse (Switzerland), Mimetas (Netherlands), and CN Bio Innovations (UK).
For more information, visit: https://www.marketsandmarkets.com/Market-Reports/lung-in-vitro-model-market-78042820.html